Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France

OBJECTIVE: The objective was to assess the real-world cost-effectiveness of rivaroxaban, versus vitamin K antagonists (VKAs), for stroke prevention in patients with atrial fibrillation (AF) from a French national health insurance perspective. METHODS: A Markov model was developed with a lifetime hor...

Descripción completa

Detalles Bibliográficos
Autores principales: Bowrin, Kevin, Briere, Jean-Baptiste, Fauchier, Laurent, Coleman, Craig, Millier, Aurélie, Toumi, Mondher, Clay, Emilie, Levy, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6980557/
https://www.ncbi.nlm.nih.gov/pubmed/31978044
http://dx.doi.org/10.1371/journal.pone.0225301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6980557/
https://www.ncbi.nlm.nih.gov/pubmed/31978044
http://dx.doi.org/10.1371/journal.pone.0225301

Ejemplares similares